IDL Diagnostics
0.38 SEK
+9.71 %
Less than 1K followers
IDLDX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for IDL Diagnostics
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 0.4 | 0.1 | 12.0 | 37.0 | 43.0 | 57.4 | 53.1 |
| growth-% | -81.0 % | 14,181.0 % | 208.4 % | 16.4 % | 33.5 % | -7.5 % | |
| EBITDA | -20.7 | -24.1 | -50.6 | -59.3 | -59.8 | -43.4 | -8.4 |
| EBIT | -20.7 | -24.1 | -50.6 | -59.3 | -59.8 | -43.4 | -12.0 |
| Profit before taxes | -20.7 | -24.1 | -50.6 | -59.3 | -59.3 | -42.5 | -12.2 |
| Net income | -20.7 | -24.1 | -50.6 | -59.3 | -59.3 | -42.5 | -12.2 |
| EPS | -0.52 | -0.31 | -0.53 | -0.28 | -0.26 | -0.18 | -0.05 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -4,680.8 % | -28,633.3 % | -421.6 % | -160.3 % | -138.9 % | -75.6 % | -15.7 % |
| EBIT-% | -4,680.8 % | -28,633.3 % | -421.6 % | -160.3 % | -138.9 % | -75.6 % | -22.6 % |
| ROE | -25.8 % | -42.8 % | -23.3 % | -26.6 % | -36.2 % | -35.0 % | -8.2 % |
| ROI | -22.7 % | -39.8 % | -22.2 % | -25.1 % | -33.9 % | -31.6 % | -6.9 % |